CQDM's 10th Anniversary
On November 19th, 2018, CQDM celebrated its 10th Anniversary with 300 people involved in the life sciences field, including members from the pharmaceutical industry, scientists from academic research institutions, entrepreneurs, partners and government representatives.
During this event, Diane Gosselin, President and CEO of CQDM, unveils a study carried out over the last 10 years, revealing the considerable economic spin-offs reflecting CQDM’s important contribution to the growth of life sciences industry in Quebec and Canada. Subsequently, some selected projects from the CQDM portfolio were also presented, interwoven with 4 important announcements that reflect the pharmaceutical sector’s enthusiasm for the collaborative model: Amgen becomes a new member of CQDM, the new financial contribution of Merck and Pfizer and the creation of the Gordon Shore Prize. Then, an artificial intelligence introduction from Uwe Schoenbeck, Senior Vice President Worldwide R&D and Chief Scientiﬁc Oﬃcer, External Science and Innovation (ERDI), Pfizer led to a panel composed of different players of the life sciences ecosystem who raised the following question: Is Pharma ready for artificial intelligence? The conference session was finally closed by Deborah Slipetz, Senior Scientist, Digital Technologies, Merck & Co., with a presentation on digital health technology.
CQDM’s 10th Anniversary presentations are available below.
Summary report on CQDM impact
CQDM's 10th Anniversary Presentations
Edward Fon, Professor, Montreal Neurological
Institute and Hospital,
François-Thomas Michaud, CEO,
Michel Bouvier, General Manager, Institute for Research in Immunology and Cancer (IRIC)
Senior VP & Chief Scientific Officer, External R&D Innovation,
Pfizer worldwide R&D
Panel: Is Pharma Ready for Artificial Intelligence?
Deborah Slipetz, distinguished scientist, Technologies numériques Merck Research Laboratories, Merck & Co.
Chief Scientist Officer of Quebec,
CQDM Board of Directors